Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
22 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
tesa Labtec GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'tesa Labtec GmbH - Product Pipeline Review - 2014', provides an overview of the tesa Labtec GmbH's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of tesa Labtec GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of tesa Labtec GmbH including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of tesa Labtec GmbH's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the tesa Labtec GmbH's pipeline products Reasons to buy - Evaluate tesa Labtec GmbH's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of tesa Labtec GmbH in its therapy areas of focus - Identify new drug targets and therapeutic classes in the tesa Labtec GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of tesa Labtec GmbH and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of tesa Labtec GmbH - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of tesa Labtec GmbH and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 tesa Labtec GmbH Snapshot 4 tesa Labtec GmbH Overview 4 Key Information 4 Key Facts 4 tesa Labtec GmbH - Research and Development Overview 5 Key Therapeutic Areas 5 tesa Labtec GmbH - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 tesa Labtec GmbH - Pipeline Products Glance 9 tesa Labtec GmbH - Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 tesa Labtec GmbH - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 tesa Labtec GmbH - Drug Profiles 11 acyclovir 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 donepezil hydrochloride 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 rasagiline 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 tesa Labtec GmbH - Pipeline Analysis 14 tesa Labtec GmbH - Pipeline Products by Target 14 tesa Labtec GmbH - Pipeline Products by Route of Administration 15 tesa Labtec GmbH - Pipeline Products by Molecule Type 16 tesa Labtec GmbH - Pipeline Products by Mechanism of Action 17 tesa Labtec GmbH - Recent Pipeline Updates 18 tesa Labtec GmbH - Dormant Projects 19 tesa Labtec GmbH - Locations And Subsidiaries 20 Head Office 20 Other Locations & Subsidiaries 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 22 Disclaimer 22
List of Tables tesa Labtec GmbH, Key Information 4 tesa Labtec GmbH, Key Facts 4 tesa Labtec GmbH - Pipeline by Indication, 2014 6 tesa Labtec GmbH - Pipeline by Stage of Development, 2014 7 tesa Labtec GmbH - Monotherapy Products in Pipeline, 2014 8 tesa Labtec GmbH - Phase I, 2014 9 tesa Labtec GmbH - Preclinical, 2014 10 tesa Labtec GmbH - Pipeline by Target, 2014 14 tesa Labtec GmbH - Pipeline by Route of Administration, 2014 15 tesa Labtec GmbH - Pipeline by Molecule Type, 2014 16 tesa Labtec GmbH - Pipeline Products by Mechanism of Action, 2014 17 tesa Labtec GmbH - Recent Pipeline Updates, 2014 18 tesa Labtec GmbH - Dormant Developmental Projects,2014 19 tesa Labtec GmbH, Other Locations 20
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.